Deferred Tax Assets, Operating Loss Carryforwards of Vitro Biopharma, Inc. from 31 Oct 2022 to 31 Oct 2025

Taxonomy & unit: us-gaap: USD
Description: Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary: Vitro Biopharma, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 31 Oct 2022 to 31 Oct 2025.
Vitro Biopharma, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Oct 2025 was $5,286,000, a 16% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)

Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Vitro Biopharma, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$5,286,000	+$724,000	+16%	31 Oct 2025	10-K	13 Feb 2026	2025	FY
Q3 2024	$4,562,000	+$1,488,000	+48%	31 Oct 2024	10-K	13 Feb 2026	2025	FY
Q3 2023	$3,074,000	+$911,000	+42%	31 Oct 2023	10-K	28 Jan 2025	2024	FY
Q3 2022	$2,163,000			31 Oct 2022	10-K	29 Jan 2024	2023	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.